Ownership history in STEMPOINT CAPITAL LP Β· 8 quarters on record
This page tracks every 13F SEC filing in which STEMPOINT CAPITAL LP reported a position in PROTARA THERAPEUTICS INC (TARA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π STEMPOINT CAPITAL LP outperformed the S&P 500 by +119.2% annually on this TARA position. Timing score: 20% (1/5 decisions correct). Average cost basis: $3.15. Maximum drawdown during holding period: β42.6%.
π₯ Exceptional β beat the S&P 500 by 119.2% per year on this position.
5 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
1 of 5 add/trim decisions correct
Best entry: $2.08 (2024 Q2) Β· Worst: $4.26 (2025 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
3 adds Β· 5 trims. Bought during 1 of 3 down-price quarters. π Predominantly trimming β distribution phase.
π STEMPOINT CAPITAL LP has been actively increasing its TARA allocation β a bullish signal from insiders.
Currently 0.32% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size